Evidence map›Paper›PMID 41158196›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Targeted UDP-glucose ceramide glucosyltransferase stable overexpression induces a metabolic switch improving cell performance at high cell density.

Marzia Rahimi, Lars K Nielsen, Jesús Lavado-García

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marzia RahimiThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
Lars K NielsenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
Jesús Lavado-GarcíaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Viral vectors such as adeno-associated viruses (AAVs) and virus-like particles (VLPs) are critical tools in gene therapy, typically produced using transient gene expression (TGE). Intensification of TGE processes to high cell densities is hampered by the cell density effect (CDE), characterized by decreased cell-specific productivity as cell density increases. Physiological changes following transfection, particularly reduced glycosphingolipid biosynthesis, have been identified as factors affecting productivity and viability. Methods: We used a targeted integration approach to generate HEK293SF-3F6 cell lines constitutively or inducibly overexpressing UDP-glucose ceramide glucosyltransferase (UGCG), the precursor enzyme responsible for glycosphingolipid biosynthesis. We evaluated how varying UGCG expression levels influenced cellular metabolism, transfection efficiency, and HIV-1 Gag VLP production. Results: Constitutive UGCG overexpression triggered a metabolic shift from glycolysis toward mitochondrial fatty acid oxidation. Moderate UGCG expression improved transfection efficiency and enhanced VLP production at high cell densities, while high UGCG expression negatively impacted cellular performance. Inducible UGCG expression further enhanced productivity under high-density conditions, highlighting the advantages of tightly regulated transgene expression. Conclusion: These findings highlight crucial metabolic adaptations linked to UGCG expression in production cell lines and underscore the value of carefully controlled UGCG expression levels for optimizing viral vector and VLP manufacturing.

Indexed as

cell density effectcell line engineeringHEK293targeted integrationUGCGvirus-like particle (VLP)

Identifiers

PMID41158196
PMCPMC12556263

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.